QIAGEN introduces QIAensemble Decapper to facilitate handling of liquid samples

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced today the launch of the QIAensemble Decapper automation system that will facilitate the handling of liquid-based cytology and various other types of liquid samples that are processed by clinical laboratories around the world.

This open platform system enables laboratories to automate many tedious manual steps required for unscrewing (or "decapping") the lids of clinical sample vials, extracting the sample material and pipetting it into testing vials and then recapping the clinical sample vial. This is considered to be a very onerous processing step due to the design of liquid cytology sample collection vials. The QIAensemble Decapper, which is considered the first instrument of its kind to be designed to support downstream molecular testing, will help to reduce the risk for injuries to laboratory staff from repetitive motions, while also eliminating the risk for variation among laboratory staff and improving productivity.

For example, a professional ergonomics evaluation of the sample preparation processing of 88 samples showed QIAensemble Decapper reduced hands-on time by 70% compared to the time required for manual processing by a laboratory worker while eliminating more than 1,200 movements.

QIAensemble Decapper has a capacity to process up to approximately 800 samples per shift (excluding set-up time and post-processing requirements). It has been designed specifically for the handling and transfer of sample materials, and the addition of reagents. The instrument accommodates a variety of fluid types of variable viscosity for both samples and reagents. The software system, which is operated by an intuitive graphical user interface (GUI), provides laboratory staff with a comprehensive and user-friendly report for each run. The software also offers chain of custody and an ability to identify samples that were not properly transferred.

QIAensemble Decapper standardizes the processing with digital data collection and is highly flexible in regards to output tube types, such as conical tubes, u-shaped tubes, BD Vacutainer® tubes and Greiner's Vacuette® tubes. Additionally, the instrument will be compatible with sample racks on the QIAsymphony SP automation system.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    QIAGEN Manchester Limited. (2019, June 20). QIAGEN introduces QIAensemble Decapper to facilitate handling of liquid samples. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20120106/QIAGEN-introduces-QIAensemble-Decapper-to-facilitate-handling-of-liquid-samples.aspx.

  • MLA

    QIAGEN Manchester Limited. "QIAGEN introduces QIAensemble Decapper to facilitate handling of liquid samples". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20120106/QIAGEN-introduces-QIAensemble-Decapper-to-facilitate-handling-of-liquid-samples.aspx>.

  • Chicago

    QIAGEN Manchester Limited. "QIAGEN introduces QIAensemble Decapper to facilitate handling of liquid samples". News-Medical. https://www.news-medical.net/news/20120106/QIAGEN-introduces-QIAensemble-Decapper-to-facilitate-handling-of-liquid-samples.aspx. (accessed November 21, 2024).

  • Harvard

    QIAGEN Manchester Limited. 2019. QIAGEN introduces QIAensemble Decapper to facilitate handling of liquid samples. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20120106/QIAGEN-introduces-QIAensemble-Decapper-to-facilitate-handling-of-liquid-samples.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
QIAGEN announces commercialization of AdnaTest kit for clinical research in prostate cancer